報價延遲最少15分鐘:2026/10/01 14:52 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
130.65 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
5.33/7.27
|
|
企業價值
9.98B
|
| 資產負債 |
|
每股賬面淨值
20.51
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
2.71B
|
|
每股收益
22.45
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide. |
